Pacific Biosciences of California (PACB) Scheduled to Post Earnings on Tuesday

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) is set to release its earnings data on Tuesday, April 30th. Persons that wish to register for the company's earnings conference call can do so using this link.

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) last released its earnings results on Thursday, February 15th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.02. The firm had revenue of $58.36 million during the quarter, compared to analyst estimates of $57.96 million. Pacific Biosciences of California had a negative net margin of 152.97% and a negative return on equity of 40.23%. The business's revenue was up 113.3% on a year-over-year basis. During the same quarter last year, the business earned ($0.35) EPS. On average, analysts expect Pacific Biosciences of California to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pacific Biosciences of California Trading Up 8.8 %

PACB stock traded up $0.13 during trading on Monday, hitting $1.60. The company had a trading volume of 8,926,629 shares, compared to its average volume of 9,814,427. The firm has a market capitalization of $428.72 million, a P/E ratio of -1.35 and a beta of 1.83. Pacific Biosciences of California has a 52-week low of $1.25 and a 52-week high of $14.55. The company has a 50 day simple moving average of $3.66 and a 200-day simple moving average of $6.34. The company has a quick ratio of 7.21, a current ratio of 7.81 and a debt-to-equity ratio of 1.27.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. JPMorgan Chase & Co. downgraded shares of Pacific Biosciences of California from an "overweight" rating to a "neutral" rating in a research note on Monday, April 22nd. Sanford C. Bernstein cut their target price on shares of Pacific Biosciences of California from $9.00 to $2.50 and set an "outperform" rating on the stock in a research report on Thursday, April 18th. The Goldman Sachs Group downgraded shares of Pacific Biosciences of California from a "buy" rating to a "neutral" rating and cut their target price for the company from $7.00 to $2.50 in a research report on Thursday, April 18th. UBS Group cut their target price on shares of Pacific Biosciences of California from $12.50 to $12.00 and set a "buy" rating on the stock in a research report on Friday, February 16th. Finally, Scotiabank cut their target price on shares of Pacific Biosciences of California from $15.00 to $8.00 and set a "sector outperform" rating on the stock in a research report on Thursday, April 18th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $7.77.

Insider Transactions at Pacific Biosciences of California

In related news, Director David W. Meline bought 40,000 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was bought at an average cost of $4.40 per share, for a total transaction of $176,000.00. Following the purchase, the director now directly owns 40,000 shares of the company's stock, valued at $176,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Oene Mark Van sold 33,560 shares of the business's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $5.96, for a total value of $200,017.60. Following the completion of the sale, the insider now owns 876,611 shares of the company's stock, valued at approximately $5,224,601.56. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director David W. Meline purchased 40,000 shares of the business's stock in a transaction that occurred on Wednesday, March 6th. The stock was bought at an average cost of $4.40 per share, with a total value of $176,000.00. Following the acquisition, the director now owns 40,000 shares in the company, valued at approximately $176,000. The disclosure for this purchase can be found here. Insiders have sold a total of 37,359 shares of company stock valued at $218,843 in the last 90 days. Insiders own 1.40% of the company's stock.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.